{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:14:29Z","timestamp":1790957669089,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.tcm.2022.04.003","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T11:38:19Z","timestamp":1650281899000},"page":"418-428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias"],"prefix":"10.1016","volume":"33","author":[{"given":"Antonis A.","family":"Manolis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora A.","family":"Manolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Melita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0336-4745","authenticated-orcid":false,"given":"Antonis S.","family":"Manolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tcm.2022.04.003_bib0001","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s40265-018-0985-4","article-title":"Cardiovascular Safety of Antihyperglycemic Agents: \"Do Good or Do No Harm\"","volume":"78","author":"Manolis","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.tcm.2022.04.003_bib0002","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/HCO.0000000000000922","article-title":"The pleiotropic cardiovascular effects of sodium-glucose cotransporter-2 inhibitors","volume":"36","author":"Tanna","year":"2021","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-020-01048-x","article-title":"The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study","volume":"19","author":"Chen","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0004","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.tcm.2022.04.003_bib0005","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","article-title":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF","volume":"42","author":"Curtain","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2022.04.003_bib0006","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","article-title":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0007","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s00059-018-4704-4","article-title":"Cardiovascular outcome in type 2 diabetes and atrial fibrillation","volume":"44","author":"Costard-J\u00e4ckle","year":"2019","journal-title":"Herz"},{"key":"10.1016\/j.tcm.2022.04.003_bib0008","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/dom.13512","article-title":"Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies","volume":"21","author":"Bell","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.tcm.2022.04.003_bib0009","doi-asserted-by":"crossref","first-page":"10887","DOI":"10.21037\/apm-21-2694","article-title":"Sodium-glucose cotransporter-2 inhibitors protect against atrial fibrillation in patients with heart failure","volume":"10","author":"Zhou","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.tcm.2022.04.003_bib0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12933-021-01243-4","article-title":"SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system","volume":"20","author":"Bonora","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0011","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s10554-020-02122-x","article-title":"Association of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: impact of SGLT2 inhibitors","volume":"37","author":"Tanaka","year":"2021","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2022.04.003_bib0012","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/ejhf.1663","article-title":"Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial","volume":"22","author":"B\u00f6hm","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.tcm.2022.04.003_bib0013","article-title":"Effect of SLGT2 Inhibitors on Patients with Atrial Fibrillation","volume":"14","author":"Haloot","year":"2021","journal-title":"J Atr Fibrillation"},{"key":"10.1016\/j.tcm.2022.04.003_bib0014","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12933-020-01162-w","article-title":"The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors","volume":"19","author":"Ling","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0015","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2022.04.003_bib0016","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12933-020-01105-5","article-title":"SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials","volume":"19","author":"Li","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.tcm.2022.04.003_bib0017","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1097\/FJC.0000000000001183","article-title":"Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials","volume":"79","author":"Zheng","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0018","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/dom.14211","article-title":"Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials","volume":"23","author":"Okunrintemi","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.tcm.2022.04.003_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022222","article-title":"Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"10","author":"Pandey","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.tcm.2022.04.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.106159","article-title":"Effects of Sodium\/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis","volume":"31","author":"Ong","year":"2022","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.tcm.2022.04.003_bib0021","article-title":"Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials","volume":"12","author":"Li","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.tcm.2022.04.003_bib0022","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12933-021-01392-6","article-title":"Empagliflozin protects the heart against ischemia\/reperfusion-induced sudden cardiac death","volume":"20","author":"Hu","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119440","article-title":"Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia","volume":"276","author":"Azam","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.tcm.2022.04.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100933","article-title":"SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis","volume":"36","author":"Cardoso","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.tcm.2022.04.003_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.691907","article-title":"Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis","volume":"8","author":"Gager","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.tcm.2022.04.003_bib0026","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2022.04.003_bib0027","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1093\/eurheartj\/ehab563","article-title":"Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure","volume":"42","author":"Light","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2022.04.003_bib0028","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/eurheartj\/ehab094","article-title":"Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial","volume":"42","author":"Heerspink","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2022.04.003_bib0029","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/europace\/euab177","article-title":"Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials","volume":"24","author":"Sfairopoulos","year":"2022","journal-title":"Europace"},{"key":"10.1016\/j.tcm.2022.04.003_bib0030","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10741-019-09804-2","article-title":"Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target","volume":"24","author":"Manolis","year":"2019","journal-title":"Heart Failure Reviews"},{"key":"10.1016\/j.tcm.2022.04.003_bib0031","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2022.04.003_bib0032","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.amjcard.2021.10.017","article-title":"A Meta-Analysis of the Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure and Preserved Ejection Fraction","volume":"164","author":"Al-Abdouh","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0033","article-title":"Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis","author":"Tsampasian","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0034","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1007\/s13300-020-00924-9","article-title":"Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design","volume":"11","author":"Fujiki","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.tcm.2022.04.003_bib0035","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/jdi.13255","article-title":"Sodium-glucose cotransporters: Functional properties and pharmaceutical potential","volume":"11","author":"Sano","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.tcm.2022.04.003_bib0036","first-page":"239","article-title":"Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors","volume":"6","author":"Yang","year":"2020","journal-title":"Chronic Dis Transl Med"},{"key":"10.1016\/j.tcm.2022.04.003_bib0037","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","article-title":"Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0038","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/eurjpc\/zwab173","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","volume":"28","author":"Zhang","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0039","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-020-01208-z","article-title":"Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF","volume":"20","author":"Bode","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12933-019-0984-0","article-title":"Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?","volume":"19","author":"Yurista","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0041","doi-asserted-by":"crossref","first-page":"e13741","DOI":"10.14814\/phy2.13741","article-title":"Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts","volume":"6","author":"Mizuno","year":"2018","journal-title":"Physiol Rep"},{"key":"10.1016\/j.tcm.2022.04.003_bib0042","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/med.21732","article-title":"Mitochondrial dysfunction in cardiovascular disease: Current status of translational research\/clinical and therapeutic implications","volume":"41","author":"Manolis","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.tcm.2022.04.003_bib0043","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.tcm.2020.04.011","article-title":"The role of the autonomic nervous system in cardiac arrhythmias: The neuro-cardiac axis, more foe than friend?","volume":"31","author":"Manolis","year":"2021","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.tcm.2022.04.003_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114674","article-title":"Dapagliflozin attenuates arrhythmic vulnerabilities by regulating connexin43 expression via the AMPK pathway in post-infarcted rat hearts","volume":"192","author":"Lee","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0045","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12933-018-0790-0","article-title":"A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats","volume":"17","author":"Durak","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0046","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects","volume":"167","author":"Dyck","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0047","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","article-title":"Direct cardiac effects of SGLT2 inhibitors","volume":"21","author":"Chen","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0048","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.017483","article-title":"Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model","volume":"10","author":"Nishinarita","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.tcm.2022.04.003_bib0049","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.tcm.2022.04.003_bib0050","first-page":"10950","article-title":"The cardioprotective effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in rats with isoproterenol-induced cardiomyopathy","volume":"13","author":"Wang","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.tcm.2022.04.003_bib0051","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12933-020-01066-9","article-title":"Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury","volume":"19","author":"Lahnwong","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0052","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12933-018-0745-5","article-title":"Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors","volume":"17","author":"Lahnwong","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0053","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002183","article-title":"Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+-Glucose Cotransport","volume":"4","author":"Lambert","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.tcm.2022.04.003_bib0054","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cvr\/cvp190","article-title":"SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states","volume":"84","author":"Banerjee","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.tcm.2022.04.003_bib0055","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium\/Glucose Cotransporter 2 Inhibitor Empagliflozin","volume":"143","author":"Philippaert","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2022.04.003_bib0056","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-3-642-41588-3_7","article-title":"The role of late I Na in development of cardiac arrhythmias","volume":"221","author":"Antzelevitch","year":"2014","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0057","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/heartjnl-2020-318060","article-title":"Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure","volume":"107","author":"Joshi","year":"2021","journal-title":"Heart"},{"key":"10.1016\/j.tcm.2022.04.003_bib0058","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/ijms20071680","article-title":"Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats","volume":"20","author":"Lee","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tcm.2022.04.003_bib0059","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.3390\/ijms22157976","article-title":"Cardioprotection by SGLT2 Inhibitors-Does It All Come Down to Na(+)?","volume":"22","author":"Trum","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tcm.2022.04.003_bib0060","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.tcm.2022.04.003_bib0061","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.3390\/ijms22116105","article-title":"Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin","volume":"22","author":"Jhuo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tcm.2022.04.003_bib0062","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011006","article-title":"Systemic Inflammation Rapidly Induces Reversible Atrial Electrical Remodeling: The Role of Interleukin-6-Mediated Changes in Connexin Expression","volume":"8","author":"Lazzerini","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.tcm.2022.04.003_bib0063","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.tcm.2022.04.003_bib0064","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2","volume":"35","author":"Matthews","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.tcm.2022.04.003_bib0065","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11906-022-01170-z","article-title":"Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition","volume":"24","author":"Herat","year":"2022","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.tcm.2022.04.003_bib0066","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.tcm.2022.04.003_bib0067","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1007\/s00125-020-05145-0","article-title":"Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes","volume":"63","author":"Gueguen","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.tcm.2022.04.003_bib0068","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5582\/ddt.2017.01069","article-title":"Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report","volume":"12","author":"Kiuchi","year":"2018","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.tcm.2022.04.003_bib0069","doi-asserted-by":"crossref","first-page":"7684","DOI":"10.3390\/ijms22147684","article-title":"Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal Gland","volume":"22","author":"Lymperopoulos","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tcm.2022.04.003_bib0070","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022637","article-title":"Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure","volume":"10","author":"Hamaoka","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.tcm.2022.04.003_bib0071","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fendo.2018.00421","article-title":"The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity","volume":"9","author":"Wan","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.tcm.2022.04.003_bib0072","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/jdi.12726","article-title":"Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials","volume":"9","author":"Sano","year":"2018","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.tcm.2022.04.003_bib0073","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano","year":"2018","journal-title":"J Cardiol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0074","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/a-1298-4205","article-title":"Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?","volume":"53","author":"Dimova","year":"2021","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.tcm.2022.04.003_bib0075","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s13300-018-0480-7","article-title":"Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale","volume":"9","author":"Kubota","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.tcm.2022.04.003_bib0076","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0077","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1002\/ehf2.12825","article-title":"Rationale and design of the EMPYREAN study","volume":"7","author":"Motoki","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.tcm.2022.04.003_bib0078","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00059-014-4086-1","article-title":"[Hypoglycemia and cardiac arrhythmia in patients with diabetes mellitus type 2]","volume":"39","author":"Hanefeld","year":"2014","journal-title":"Herz"},{"key":"10.1016\/j.tcm.2022.04.003_bib0079","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1475-2840-12-70","article-title":"The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study","volume":"12","author":"Ring","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0080","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2337\/diabetes.52.6.1469","article-title":"Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia","volume":"52","author":"Robinson","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.tcm.2022.04.003_bib0081","doi-asserted-by":"crossref","first-page":"53","DOI":"10.33963\/KP.15666","article-title":"Empagliflozin significantly attenuates sotalol-induced QTc prolongation in rats","volume":"79","author":"\u00d6zg\u00fcr Bar\u0131\u015f","year":"2021","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0082","first-page":"203","article-title":"The implications of obesity for cardiac arrhythmia mechanisms and management","volume":"31","author":"Pathak","year":"2015","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0083","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12933-021-01285-8","article-title":"The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor","volume":"20","author":"Chan","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0084","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1007\/s11695-021-05385-y","article-title":"Evaluation of Changes in Ventricular Repolarization Parameters in Morbidly Obese Patients Undergoing Bariatric Surgery","volume":"31","author":"Ibisoglu","year":"2021","journal-title":"Obes Surg"},{"key":"10.1016\/j.tcm.2022.04.003_bib0085","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pcad.2018.04.004","article-title":"Obesity and Ventricular Repolarization: a Comprehensive Review","volume":"61","author":"Omran","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.tcm.2022.04.003_bib0086","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/obr.12390","article-title":"Effect of obesity and weight loss on ventricular repolarization: a systematic review and meta-analysis","volume":"17","author":"Omran","year":"2016","journal-title":"Obes Rev"},{"key":"10.1016\/j.tcm.2022.04.003_bib0087","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.tcm.2022.04.003_bib0088","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/MNH.0000000000000767","article-title":"Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system","volume":"31","author":"Azzam","year":"2022","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.tcm.2022.04.003_bib0089","first-page":"25","article-title":"The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i","author":"Cianciolo","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.tcm.2022.04.003_bib0090","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.30727","article-title":"Potential roles of sodium-glucose co-transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure","author":"Attachaipanich","year":"2022","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0091","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jcb.10631","article-title":"Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1)","volume":"90","author":"Zhou","year":"2003","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.tcm.2022.04.003_bib0092","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","article-title":"Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target","volume":"243","author":"Di Franco","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.tcm.2022.04.003_bib0093","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm1613","article-title":"Endothelial-to-mesenchymal transition contributes to cardiac fibrosis","volume":"13","author":"Zeisberg","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.tcm.2022.04.003_bib0094","doi-asserted-by":"crossref","first-page":"7642","DOI":"10.1111\/jcmm.16601","article-title":"Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK\u03b1\/TGF-\u03b2\/Smad signalling in type 2 diabetic rats","volume":"25","author":"Tian","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.tcm.2022.04.003_bib0095","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ahj.2022.01.008","article-title":"Ertugliflozin to reduce arrhythmic burden in ICD\/CRT patients (ERASe-trial) - A phase III study","volume":"246","author":"von Lewinski","year":"2022","journal-title":"Am Heart J"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173822000627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173822000627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T05:02:47Z","timestamp":1760936567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173822000627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":95,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1050173822000627"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2022.04.003","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2022.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}